These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23558218)

  • 41. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA).
    Goldsmith D; Covic A
    Nephrol Dial Transplant; 2010 Jun; 25(6):1734-7. PubMed ID: 20200007
    [No Abstract]   [Full Text] [Related]  

  • 42. Management of anemia in heart failure.
    Stamos TD; Silver MA
    Curr Opin Cardiol; 2010 Mar; 25(2):148-54. PubMed ID: 19996965
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
    Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill J; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R; Uno H;
    Am J Kidney Dis; 2009 Jul; 54(1):59-69. PubMed ID: 19501439
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Recent advances on the use of erythropoietin in oncology].
    Spaëth D
    Bull Cancer; 2006 May; 93(5):489-93. PubMed ID: 16777627
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The TREAT study answers a question, not the question.
    Coyne DW
    Am J Kidney Dis; 2008 Sep; 52(3):626-7; author reply 627-8. PubMed ID: 18725019
    [No Abstract]   [Full Text] [Related]  

  • 46. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia".
    Coiffier B
    Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359
    [No Abstract]   [Full Text] [Related]  

  • 48. An ongoing study of anemia correction in chronic kidney disease.
    Pfeffer MA;
    N Engl J Med; 2007 Mar; 356(9):959-61. PubMed ID: 17329707
    [No Abstract]   [Full Text] [Related]  

  • 49. Anemia in heart failure:current evidence and challenges.
    Tang WH
    Rev Cardiovasc Med; 2007; 8(2):78-86. PubMed ID: 17603426
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Darbepoetin alpha coming of age.
    Pedrazzoli P; Cinieri S; Lorusso V; Gamucci T; Secondino S; Silvestris N
    Anticancer Res; 2007; 27(6C):4419-24. PubMed ID: 18214054
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Diagnosis and treatment of anemia in heart failure patients].
    Santilli G; Tarantini L; Baio P; Senni M
    G Ital Cardiol (Rome); 2011 May; 12(5):319-26. PubMed ID: 21593950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic kidney disease anemia management: what should be done?
    Szczech LA
    Blood Purif; 2011; 31(1-3):186-8. PubMed ID: 21228588
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Darbepoetin alfa and chronic kidney disease.
    Locatelli F; Del Vecchio L; Casartelli D
    N Engl J Med; 2010 Feb; 362(7):654-5; author reply 655. PubMed ID: 20187259
    [No Abstract]   [Full Text] [Related]  

  • 54. Anemia in chronic heart failure: can EPO reduce deaths?
    Iyengar S; Abraham WT
    Cleve Clin J Med; 2005 Nov; 72(11):1027-32. PubMed ID: 16315441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
    Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Anemia as complication of chronic heart failure: prevalence, treatment, prognosis].
    Tereshchenko SN; Atroshchenko ES; Uskach TM; Kudinova AA; Riabinina MN
    Ter Arkh; 2008; 80(9):90-5. PubMed ID: 19555048
    [No Abstract]   [Full Text] [Related]  

  • 57. Treatment of anemia with darbepoetin alfa in systolic heart failure.
    Swedberg K; Young JB; Anand IS; Cheng S; Desai AS; Diaz R; Maggioni AP; McMurray JJ; O'Connor C; Pfeffer MA; Solomon SD; Sun Y; Tendera M; van Veldhuisen DJ; ;
    N Engl J Med; 2013 Mar; 368(13):1210-9. PubMed ID: 23473338
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa.
    Longfield V; Gebhart B; Hayward L
    J Support Oncol; 2005; 3(6 Suppl 4):8-9. PubMed ID: 16355548
    [No Abstract]   [Full Text] [Related]  

  • 59. Darbepoetin alfa and history of thromboembolic events.
    Ferretti G; Felici A; Cognetti F
    J Clin Oncol; 2009 Nov; 27(33):e211; author reply e212. PubMed ID: 19858373
    [No Abstract]   [Full Text] [Related]  

  • 60. Treatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor.
    Rose S; Ali Y; Maffei B; Saidi P
    Am J Hematol; 2007 Mar; 82(3):245-6. PubMed ID: 16924646
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.